EUVIMEDEUVIMED entdecken
Crossref

Identification of Key Genes and Pathways in ESCC: Distinct Molecular Signatures Associated with Radiotherapy

Babak Salimi, Masoumeh Nomani

Current Genetic Medicine Reports · 14.11.2026 · 14 (1)

DOI: 10.1007/s40142-026-00281-2 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Current Genetic Medicine Reports, online erschienen am 14.11.2026. Verfasst von Babak Salimi und 1 weiteren Autor:innen. Die Arbeit nennt 51 Literaturangaben.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Purpose

Esophageal squamous cell carcinoma (ESCC) represents the most prevalent form of esophageal cancer. Understanding the molecular mechanisms underlying tumor progression and radiotherapy response is essential for bypassing drug resistance. Merging transcriptomic datasets from multiple sources affords the possibility to identify strong biomarkers and pathways that drive tumor behavior and therapeutic response.

Methods

Four GEO datasets were retrieved and analyzed using Transcriptome Analysis Console (TAC) to identify differentially expressed genes. The STRING database was utilized to construct protein–protein interaction (PPI) networks, which were subsequently analyzed using Cytoscape and visualized via Gephi. Functional annotation and pathway enrichment analyses were conducted using ShinyGO. Gene expression and histology‑stratified comparisons were evaluated using UALCAN based on the TCGA esophageal carcinoma cohort, and the prognostic value of the candidate genes was assessed within the ESCC cohort using the Kaplan–Meier Plotter. Finally, potential therapeutic interactions were explored in silico through ShinyGO.

Results

Integrative transcriptomic analysis identified seven core hub genes, including six genes common to both the radiotherapy and non‑radiotherapy cohorts (CXCL9, CXCL10, CCR5, TYROBP, LCP2, and FOS) and one gene specific to the non‑radiotherapy cohort (LOX). Pathway enrichment analysis revealed that radiotherapy‑associated networks were predominantly involved in antigen processing and presentation, chemokine signaling, and GPCR‑mediated immune activation. Furthermore, in silico drug–gene interaction analysis identified oxaliplatin, peginterferon alfa‑2a, atorvastatin, and ritonavir as potential candidate compounds for further investigation, particularly given their possible immunomodulatory or radiosensitizing effects in ESCC.

Conclusion

This integrative multi-cohort analysis provides insights into key molecular pathways underlying ESCC progression and radiotherapy response, identifying potential prognostic biomarkers and candidate compounds for future preclinical validation.

Zitieren

APA

Salimi, B., & Nomani, M. (2026). Identification of Key Genes and Pathways in ESCC: Distinct Molecular Signatures Associated with Radiotherapy. Current Genetic Medicine Reports, 14(1). https://doi.org/10.1007/s40142-026-00281-2

Vancouver

Salimi B, Nomani M. Identification of Key Genes and Pathways in ESCC: Distinct Molecular Signatures Associated with Radiotherapy. Current Genetic Medicine Reports. 2026;14(1). doi:10.1007/s40142-026-00281-2

BibTeX
@article{Salimi2026,
  author = {Salimi, Babak and Nomani, Masoumeh},
  title = {Identification of Key Genes and Pathways in ESCC: Distinct Molecular Signatures Associated with Radiotherapy},
  journal = {Current Genetic Medicine Reports},
  year = {2026},
  volume = {14},
  number = {1},
  doi = {10.1007/s40142-026-00281-2}
}
Kostenlos starten →